BIO Plans Lobbying Push To Improve Payments For Diagnostics
This article was originally published in The Gray Sheet
Executive SummaryThe Biotechnology Industry Organization is adding its lobbying muscle to diagnostic industry efforts to improve payment policies for molecular tests, hoping for a warm reception from lawmakers who are already focused on personalized medicine issues.
You may also be interested in...
Whitaker, appointed as the next CEO of AdvaMed, currently runs day-to-day operations at the Biotechnology Innovation Organization and has held high-level posts at HHS. Among his accomplishments, Whitaker led the legislative office at HHS when the first device user fee bill was passed in 2002.